DGAP-News: Cannovum AG
/ Key word(s): Product Launch
Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has signed a supply agreement for full-spectrum cannabis extracts through its licensed subsidiary, Cannovum Health eG. The manufacturer is a non-European pharmaceutical company with many years of experience in the extraction process. The extracts are distributed to pharmacies under Cannovum's own brand.
Herbal medicines develop their complete effect through the interaction of all herbal substances, the commonly called entourage effect. This important mode of action is preserved in cannabis extracts obtained from the full spectrum of the plant.
Cannabis extracts are becoming increasingly important in the market across Europe. In Germany, steady growth is emerging over the last three years, with pharmacy purchases of extracts rising from 4.8 liters in 2017 to more than 1,300 liters in 2020, with the first half of last year alone seeing a 63% growth in purchase volume.
"We want to supply patients in Germany and Europe with medical cannabis. Full-spectrum extracts play an important role in this, because their mode of action and ease of oral application offer another therapeutic option. This allows us to cover the full therapeutic spectrum and reach a large patient group," says Pia Marten, CEO of Cannovum AG.
The inclusion of cannabis extracts in the product portfolio is an important step towards making cannabis-based therapies possible across the board. Cannovum supports physicians and pharmacists in caring for patients through a complete medical cannabis portfolio. This gives physicians the opportunity to fully customize the therapy for their patients, because every patient deserves the best therapy.
Linda Rasch, IR & PR, Cannovum AG
For more information, visit www.cannovum.com
|Rheinsberger Str. 76/77
|+49 (0)30 3982 16360
|Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
|EQS News ID:
|End of News
|DGAP News Service